PRMT5 and cervical carcinoma: In patients with cervical cancer from the TCGA cohort, higher levels of PRMT5 expression were associated with worse outcomes in overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) (Figure 1E–G).